Work

Current clinical development of PI3K pathway inhibitors in glioblastoma

Year: 2012

Type: article

Abstract: Glioblastoma (GBM) is the most common and lethal primary malignant tumor of the central nervous system, and effective therapeutic options are lacking. The phosphatidylinositol 3-kinase (PI3K) pathway is frequently dysregulated in many human cancers, including GBM. Agents inhibiting PI3K and its effectors have demonstrated preliminary activity in various tumor types and have the potential to change the clinical treatment landscape of patients with solid tumors. In this review, we describe the activation of the PI3K pathway in GBM, explore why inhibition of this pathway may be a compelling therapeutic target for this disease, and provide an update of the data on PI3K inhibitors in clinical trials and from earlier investigation.

Source: Neuro-Oncology

DOI: 10.1093/neuonc/nos117

Authors: P. Y. Wen, E. Q. Lee, D. A. Reardon, K. L. Ligon, W. K. Alfred Yung